Franklyn Health is proud to announce that its CEO, Rob Bedford, was invited to speak at the London Pioneer Group Launch Programme Accelerator, sharing his expertise with a cohort of emerging MedTech and life sciences start-ups. The invitation reflects Franklyn Health’s growing reputation as an industry leader in MedTech clinical research, regulatory strategy, and US market access.

Addressing the accelerator’s start-up cohort, Rob delivered a high-level overview of what it really takes to bring a medical technology to the US market — still the world’s largest and often highest-priority launch destination for medical device and diagnostics companies, alongside the EU.

Trusted to Guide Emerging MedTech and Life Sciences Innovators

Being asked to speak at a leading accelerator programme is a clear signal of Franklyn Health’s standing within the global MedTech and life sciences ecosystem. Franklyn Health is increasingly called upon to support and mentor ambitious founders at the earliest stages of their journey.

At Franklyn Health, the team has supported companies of all sizes through PMA (Premarket Approval) and a wide range of FDA regulatory pathways — making it a trusted partner for medical device and diagnostics manufacturers navigating the complex route to the US market. For Rob and the team, spending time with start-ups at the very start of that journey is always a highlight.

Purpose-Built for Emerging MedTech

Franklyn Health is purpose-built to partner with ambitious medical device and diagnostics manufacturers, helping them develop clinical strategy, solve complex regulatory challenges, and bring new technologies to market, faster.

Are you a MedTech company looking for a CRO that understands your product, your pace, and your purpose?

Partner with Franklyn Health, where expertise meets agility, and your innovation becomes our mission.

Contact us to discuss your next medical device or diagnostic clinical study.